Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease

Overview

Journal Gut Liver

Specialty Gastroenterology

Date 2020 Oct 7

PMID 33024062

Citations 2

Authors

Ju Young Kim

Yoon Lee

Byung-Ho Choe

Ben Kang

Affiliations

Soon will be listed here.

Abstract

Background/aims: Anti-drug antibodies (ADAs) can develop during treatment with anti-tumor necrosis factor (TNF) agents. We aimed to investigate the factors associated with immunogenicity of anti-TNF agents in pediatric patients with inflammatory bowel disease (IBD) and observe the clinical course of ADA-positive patients.

Methods: Pediatric IBD patients receiving maintenance treatment with anti-TNF agents who had been tested for ADAs against infliximab (IFX) or adalimumab (ADL) were included in this crosssectional study. Factors associated with ADA positivity were investigated by analyzing clinicodemographic, laboratory, and treatment-related factors.

Results: A total of 76 patients (Crohn's disease, 65; ulcerative colitis, 11) were included. Among these, 59 and 17 patients were receiving IFX and ADL, respectively. ADAs were found in 10 patients (13.2%), all of whom were receiving IFX. According to multivariable logistic regression analysis, the IFX trough level (TL) was associated with ADA positivity (odds ratio, 0.25; 95% confidence interval [CI], 0.08 to 0.51; p=0.002). According to the receiver operating characteristic analysis, the optimal cutoff of the IFX TLs for stratifying patients based on the presence of ADAs against IFX was 1.88 μg/mL (area under curve, 0.941; 95% CI, 0.873 to 1.000; sensitivity, 80.0%; specificity, 95.9%; p<0.001). Among the 10 patients with ADAs against IFX, five patients (50%) switched to ADL within 1 year, while five patients (50%) kept receiving IFX. Transient ADAs were observed in three patients (30%).

Conclusions: IFX TL was the only factor associated with ADA formation in pediatric IBD patients receiving IFX. Future studies based on serial and proactive therapeutic drug monitoring are required in the future.

Citing Articles

Infliximab adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease.

Kim E, Kang B World J Gastroenterol. 2023; 29(18):2784-2797.

PMID: 37274072 PMC: 10237103. DOI: 10.3748/wjg.v29.i18.2784.

Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives.

Smeijsters E, van der Elst K, Visch A, Gobel C, Loeff F, Rispens T Pharmaceutics. 2023; 15(5).

PMID: 37242719 PMC: 10222829. DOI: 10.3390/pharmaceutics15051477.

References

Ma C, Battat R, Jairath V, Vande Casteele N . Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2019; 17(1):127-145. DOI: 10.1007/s11938-019-00222-9. View

Qiu Y, Mao R, Chen B, Zhang S, Guo J, He Y . Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. Clin Gastroenterol Hepatol. 2017; 15(9):1359-1372.e6. DOI: 10.1016/j.cgh.2017.02.005. View

Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S . Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2014; 13(6):1103-10. DOI: 10.1016/j.cgh.2014.11.026. View

Lichtenstein G, Diamond R, Wagner C, Fasanmade A, Olson A, Marano C . Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009; 30(3):210-26. DOI: 10.1111/j.1365-2036.2009.04027.x. View

OMeara S, Nanda K, Moss A . Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013; 20(1):1-6. DOI: 10.1097/01.MIB.0000436951.80898.6d. View

Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O . The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2013; 63(8):1258-64. DOI: 10.1136/gutjnl-2013-305259. View

Kang B, Choi S, Choi Y, Lee S, Baek S, Sohn I . Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease. J Crohns Colitis. 2018; 13(2):189-197. DOI: 10.1093/ecco-jcc/jjy155. View

Feuerstein J, Nguyen G, Kupfer S, Falck-Ytter Y, Singh S . American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017; 153(3):827-834. DOI: 10.1053/j.gastro.2017.07.032. View

Levine A, Koletzko S, Turner D, Escher J, Cucchiara S, de Ridder L . ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2013; 58(6):795-806. DOI: 10.1097/MPG.0000000000000239. View

10.

Louis E, Mary J, Vernier-Massouille G, Grimaud J, Bouhnik Y, Laharie D . Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2011; 142(1):63-70.e5. DOI: 10.1053/j.gastro.2011.09.034. View

11.

Kim S . Surgery in Pediatric Crohn's Disease: Indications, Timing and Post-Operative Management. Pediatr Gastroenterol Hepatol Nutr. 2017; 20(1):14-21. PMC: 5385302. DOI: 10.5223/pghn.2017.20.1.14. View

12.

Rosen M, Dhawan A, Saeed S . Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr. 2015; 169(11):1053-60. PMC: 4702263. DOI: 10.1001/jamapediatrics.2015.1982. View

13.

Carman N, Mack D, Benchimol E . Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2018; 20(5):18. DOI: 10.1007/s11894-018-0623-z. View

14.

Kang B, Lee Y, Lee K, Choi Y, Choe Y . Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study. Inflamm Bowel Dis. 2018; 24(3):607-616. DOI: 10.1093/ibd/izx047. View

15.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

16.

Roblin X, Riviere P, Flamant M, Veyrard P, Poullenot F, Paul S . Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 24(9):1904-1909. DOI: 10.1093/ibd/izy069. View

17.

Choi J, Kang B, Kim M, Sohn I, Lee H, Choe Y . Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients. Gut Liver. 2018; 12(3):255-262. PMC: 5945256. DOI: 10.5009/gnl17290. View

18.

Choi S, Kang B, Lee J, Choe Y . Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver. 2016; 11(1):55-61. PMC: 5221861. DOI: 10.5009/gnl16041. View

19.

Kansen H, van Rheenen P, Houwen R, Tjon A Ten W, Damen G, Kindermann A . Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators. J Pediatr Gastroenterol Nutr. 2017; 65(4):425-429. DOI: 10.1097/MPG.0000000000001551. View

20.

Ben-Horin S, Chowers Y, Ungar B, Kopylov U, Loebstein R, Weiss B . Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther. 2015; 42(3):356-64. DOI: 10.1111/apt.13268. View